Compare HUM & ZBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUM | ZBH |
|---|---|---|
| Founded | 1961 | 1927 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.5B | 19.5B |
| IPO Year | 2002 | 2001 |
| Metric | HUM | ZBH |
|---|---|---|
| Price | $214.13 | $90.83 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 20 | 20 |
| Target Price | ★ $238.65 | $104.56 |
| AVG Volume (30 Days) | 1.5M | ★ 1.7M |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | ★ 1.65% | 1.04% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 9.84 | 3.55 |
| Revenue | ★ $129,664,000,000.00 | $8,231,500,000.00 |
| Revenue This Year | $26.15 | $4.96 |
| Revenue Next Year | $6.07 | $3.76 |
| P/E Ratio | ★ $21.71 | $25.96 |
| Revenue Growth | ★ 10.11 | 7.20 |
| 52 Week Low | $163.11 | $84.59 |
| 52 Week High | $315.35 | $108.29 |
| Indicator | HUM | ZBH |
|---|---|---|
| Relative Strength Index (RSI) | 70.89 | 43.90 |
| Support Level | $206.87 | $88.91 |
| Resistance Level | $285.02 | $95.31 |
| Average True Range (ATR) | 6.73 | 2.30 |
| MACD | 2.56 | -0.15 |
| Stochastic Oscillator | 74.14 | 19.11 |
Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.